시장보고서 | 연간정보서비스 | 맞춤형시장조사 | 메일링 | 샘플 요청 목록
세계의 미세소관 억제제 화학요법 의약품 시장 보고서(2025년)
Microtubule Inhibitor Chemotherapy Drugs Global Market Report 2025
상품코드 : 1760637
리서치사 : The Business Research Company
발행일 : On Demand Report
페이지 정보 : 영문 175 Pages
 라이선스 & 가격 (부가세 별도)
US $ 4,490 ￦ 6,337,000
PDF (Single User License) help
PDF 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.
US $ 6,490 ￦ 9,160,000
PDF (Site License) help
PDF 보고서를 동일 사업장의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.
US $ 8,490 ￦ 11,983,000
PDF (Enterprise License) help
PDF 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.


ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
ㅁ 보고서에 따라 최신 정보로 업데이트하여 보내드립니다. 배송기일은 문의해 주시기 바랍니다.

한글목차

미세소관 억제제 화학요법 의약품 시장 규모는 향후 몇 년 동안 강력한 성장을 보일 것으로 예상됩니다. 예측 기간 동안의 성장은 암 발병률의 증가, 고령화 인구 확대, 암에 대한 인식 제고, 화학요법 옵션의 증가, 정부의 지원 정책에 기인할 수 있습니다. 예측 기간 동안의 주요 동향으로는 의약품 제형의 개선, 제네릭 의약품의 공급 확대, 병용 요법의 개발, 나노 기술의 발전, 약물 전달 메커니즘의 개선 등이 있습니다.

암 발병률의 증가는 미세소관 억제제 화학요법 약물의 시장 성장을 촉진할 것으로 예상됩니다. 암은 주변 조직을 침범하거나 전신으로 전이될 가능성이 있는 비정상적인 세포 증식을 특징으로 하는 질병을 총칭합니다. 고령 인구는 암 발병 건수의 증가에 크게 기여하고 있습니다. 고령자는 유전적 변이가 축적되기 쉽고 발암 물질에 장기간 노출될 가능성이 높기 때문에 암 발병 위험이 높기 때문입니다. 미세소관 억제제 화학요법 약물은 세포 분열에 필수적인 미세소관을 표적으로 하여 세포 분열을 방해함으로써 암을 치료하는 데 사용되며, 이를 통해 암세포의 급속한 증식을 막습니다. 예를 들어, 2024년 2월, 스위스에 본부를 둔 정부 간 기구인 세계보건기구(WHO)는 전 세계 암 발병 건수가 2022년 2,000만 건에서 2050년에는 3,500만 건 이상으로 크게 증가할 것으로 전망했습니다. 그 결과, 암 발병률이 증가하면서 미세소관 억제제 화학요법 약물에 대한 수요도 증가하고 있습니다.

미세소관 억제제 화학요법 의약품 시장의 선도 기업들은 종양에 대한 의약품 전달을 개선하기 위해 알부민 결합 제제 등 혁신적인 솔루션에 집중하고 있습니다. 알부민 결합 제제는 의약품의 용해도, 안정성 및 암세포로의 표적 전달을 향상시키는 단백질인 알부민에 결합된 활성 제약 성분으로 구성되어 있습니다. 예를 들어, 2024년 10월, 스위스에 본사를 둔 제약 회사인 Sandoz AG는 미국에서 파클리탁셀의 제네릭 의약품을 출시했습니다. 이 새로운 제제는 주사용 동결 건조 분말로, 1회용 100mg 바이알로 제공됩니다. 파클리탁셀 단백질 결합 입자 주사 현탁액(알부민 결합형)은 미세관 억제제로, 전이성 유방암 환자에게 전이성 질환에 대한 복합 화학요법에 반응하지 않았거나 보조 화학요법 후 6개월 이내에 재발한 경우 치료에 사용됩니다.

목차

제1장 주요 요약

제2장 시장 특징

제3장 시장 동향과 전략

제4장 시장 - 금리, 인플레이션, 지정학, 무역전쟁과 관세, 코로나 19 및 회복이 시장에 미치는 영향을 포함한 거시경제 시나리오

제5장 세계의 성장 분석과 전략 분석 프레임워크

제6장 시장 세분화

제7장 지역별, 국가별 분석

제8장 아시아태평양 시장

제9장 중국 시장

제10장 인도 시장

제11장 일본 시장

제12장 호주 시장

제13장 인도네시아 시장

제14장 한국 시장

제15장 서유럽 시장

제16장 영국 시장

제17장 독일 시장

제18장 프랑스 시장

제19장 이탈리아 시장

제20장 스페인 시장

제21장 동유럽 시장

제22장 러시아 시장

제23장 북미 시장

제24장 미국 시장

제25장 캐나다 시장

제26장 남미 시장

제27장 브라질 시장

제28장 중동 시장

제29장 아프리카 시장

제30장 경쟁 구도와 기업 프로파일

제31장 기타 주요 기업 및 혁신 기업

제32장 세계 시장 경쟁 벤치마킹과 대시보드

제33장 주요 인수합병(M&A)

제34장 최근 시장 동향

제35장 시장의 잠재력이 높은 국가, 부문, 전략

제36장 부록

HBR
영문 목차

영문목차

Microtubule inhibitor chemotherapy drugs are anticancer agents that target the function of microtubules, which play a crucial role in cell division. By disrupting the normal formation and breakdown of microtubules during mitosis, these drugs prevent cancer cells from dividing properly, thereby inhibiting tumor growth.

The primary types of microtubule inhibitor chemotherapy drugs include vinca alkaloids, taxanes, epothilones, and others. Vinca alkaloids, derived from the periwinkle plant, work by binding to tubulin a protein that makes up microtubules and preventing their assembly. These drugs act as spindle poisons, microtubule stabilizers, microtubule destabilizers, or dual-action inhibitors. They can be administered via intravenous (IV), oral, subcutaneous, and intraperitoneal routes. Vinca alkaloids are used to treat various cancers, including breast cancer, lung cancer, ovarian cancer, lymphomas, and others, and they are applicable to pediatric, adult, geriatric patients, with some gender-specific considerations.

The microtubule inhibitor chemotherapy drugs market research report is one of a series of new reports from The Business Research Company that provides microtubule inhibitor chemotherapy drugs market statistics, including microtubule inhibitor chemotherapy drugs industry global market size, regional shares, competitors with a microtubule inhibitor chemotherapy drugs market share, detailed microtubule inhibitor chemotherapy drugs market segments, market trends and opportunities, and any further data you may need to thrive in the microtubule inhibitor chemotherapy drugs industry. This microtubule inhibitor chemotherapy drugs market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The microtubule inhibitor chemotherapy drugs market size has grown strongly in recent years. It will grow from $5.17 billion in 2024 to $5.50 billion in 2025 at a compound annual growth rate (CAGR) of 6.5%. The growth during the historic period can be attributed to the expansion of precision medicine, a rise in research on targeted cancer therapies, the increasing prevalence of metastatic cancer, higher healthcare investments, and a growing emphasis on improving cancer survival rates.

The microtubule inhibitor chemotherapy drugs market size is expected to see strong growth in the next few years. It will grow to $6.99 billion in 2029 at a compound annual growth rate (CAGR) of 6.2%. The growth in the forecast period can be attributed to the rising incidence of cancer, an expanding aging population, increased cancer awareness, a growing number of chemotherapy options, and supportive government initiatives. Key trends during the forecast period include enhancements in drug formulations, greater availability of generic drugs, the development of combination therapies, advancements in nanotechnology, and improvements in drug delivery mechanisms.

The rising incidence of cancer is expected to propel the growth of the microtubule inhibitor chemotherapy drugs market. Cancer encompasses a group of diseases characterized by abnormal cell growth with the potential to invade nearby tissues or spread throughout the body. The aging population contributes significantly to the increasing number of cancer cases, as older individuals are more prone to accumulate genetic mutations and face prolonged exposure to carcinogens, heightening their risk of developing cancer. Microtubule inhibitor chemotherapy drugs are used to treat cancer by disrupting cell division through targeting microtubules, which are essential for mitosis, thereby halting the rapid proliferation of cancer cells. For example, in February 2024, the World Health Organization, an intergovernmental organization based in Switzerland, reported that global cancer cases are projected to increase substantially-from 20 million in 2022 to more than 35 million by 2050. As a result, the growing prevalence of cancer is fueling the demand for microtubule inhibitor chemotherapy drugs.

Leading companies in the microtubule inhibitor chemotherapy drugs market are concentrating on innovative solutions, such as albumin-bound formulations, to improve drug delivery to tumors. Albumin-bound formulations consist of active pharmaceutical ingredients linked to albumin, a protein that enhances drug solubility, stability, and targeted delivery to cancer cells. For instance, in October 2024, Sandoz AG, a pharmaceutical company based in Switzerland, launched its generic version of paclitaxel in the U.S. This new formulation is a lyophilized powder for injection, available in a single-dose 100 mg vial. Paclitaxel protein-bound particles for injectable suspension (albumin-bound), a microtubule inhibitor, are indicated for treating metastatic breast cancer in patients who have not responded to combination chemotherapy for metastatic disease or have relapsed within six months of adjuvant chemotherapy.

In March 2024, Johnson & Johnson, a U.S.-based pharmaceutical firm, acquired Ambrx Biopharma Inc. for $2.0 billion. This acquisition supports the advancement of ARX517, a PSMA-targeting antibody-drug conjugate (ADC) with the potential to become a first- and best-in-class treatment for metastatic castration-resistant prostate cancer. Ambrx Biopharma Inc., a U.S.-based company, specializes in developing ADCs that deliver powerful chemotherapeutic agents, including microtubule inhibitors.

Major players in the microtubule inhibitor chemotherapy drugs market are Pfizer Inc., Sanofi S.A., Bristol-Myers Squibb Company, Fresenius Kabi AG, Eli Lilly and Company, Teva Pharmaceutical Industries Ltd., Intas Pharmaceuticals Ltd., Sun Pharmaceutical Industries Limited, Eisai Co. Ltd., Aurobindo Pharma Limited, Dr. Reddy's Laboratories Ltd., Cipla Limited, Hikma Pharmaceuticals PLC, Zydus Lifesciences Limited, Gland Pharma Limited, Natco Pharma Limited, Minakem, Selleck Chemicals LLC, Accord Healthcare Ltd., Focus Biomolecules LLC.

North America was the largest region in the microtubule inhibitor chemotherapy drugs market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in microtubule inhibitor chemotherapy drugs report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the microtubule inhibitor chemotherapy drugs market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The microtubule inhibitor chemotherapy drugs market consists of supportive care medications, diagnostic agents and biomarkers, biosimilars and generics. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Microtubule Inhibitor Chemotherapy Drugs Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on microtubule inhibitor chemotherapy drugs market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

Where is the largest and fastest growing market for microtubule inhibitor chemotherapy drugs ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The microtubule inhibitor chemotherapy drugs market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

Scope

Table of Contents

1. Executive Summary

2. Microtubule Inhibitor Chemotherapy Drugs Market Characteristics

3. Microtubule Inhibitor Chemotherapy Drugs Market Trends And Strategies

4. Microtubule Inhibitor Chemotherapy Drugs Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market

5. Global Microtubule Inhibitor Chemotherapy Drugs Growth Analysis And Strategic Analysis Framework

6. Microtubule Inhibitor Chemotherapy Drugs Market Segmentation

7. Microtubule Inhibitor Chemotherapy Drugs Market Regional And Country Analysis

8. Asia-Pacific Microtubule Inhibitor Chemotherapy Drugs Market

9. China Microtubule Inhibitor Chemotherapy Drugs Market

10. India Microtubule Inhibitor Chemotherapy Drugs Market

11. Japan Microtubule Inhibitor Chemotherapy Drugs Market

12. Australia Microtubule Inhibitor Chemotherapy Drugs Market

13. Indonesia Microtubule Inhibitor Chemotherapy Drugs Market

14. South Korea Microtubule Inhibitor Chemotherapy Drugs Market

15. Western Europe Microtubule Inhibitor Chemotherapy Drugs Market

16. UK Microtubule Inhibitor Chemotherapy Drugs Market

17. Germany Microtubule Inhibitor Chemotherapy Drugs Market

18. France Microtubule Inhibitor Chemotherapy Drugs Market

19. Italy Microtubule Inhibitor Chemotherapy Drugs Market

20. Spain Microtubule Inhibitor Chemotherapy Drugs Market

21. Eastern Europe Microtubule Inhibitor Chemotherapy Drugs Market

22. Russia Microtubule Inhibitor Chemotherapy Drugs Market

23. North America Microtubule Inhibitor Chemotherapy Drugs Market

24. USA Microtubule Inhibitor Chemotherapy Drugs Market

25. Canada Microtubule Inhibitor Chemotherapy Drugs Market

26. South America Microtubule Inhibitor Chemotherapy Drugs Market

27. Brazil Microtubule Inhibitor Chemotherapy Drugs Market

28. Middle East Microtubule Inhibitor Chemotherapy Drugs Market

29. Africa Microtubule Inhibitor Chemotherapy Drugs Market

30. Microtubule Inhibitor Chemotherapy Drugs Market Competitive Landscape And Company Profiles

31. Microtubule Inhibitor Chemotherapy Drugs Market Other Major And Innovative Companies

32. Global Microtubule Inhibitor Chemotherapy Drugs Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Microtubule Inhibitor Chemotherapy Drugs Market

34. Recent Developments In The Microtubule Inhibitor Chemotherapy Drugs Market

35. Microtubule Inhibitor Chemotherapy Drugs Market High Potential Countries, Segments and Strategies

36. Appendix

(주)글로벌인포메이션 02-2025-2992 kr-info@giikorea.co.kr
ⓒ Copyright Global Information, Inc. All rights reserved.
PC버전 보기